CardioDx abandons IPO plans; AltheaDx eyes $69M IPO; Assurex Health ropes in $30M for neuropsychiatric pharmacogenomics products;

> CardioDx nixed its plans for an IPO, citing unfavorable market conditions. More

> Molecular diagnostics outfit AltheaDx filed plans for a $69 million initial public offering. Story (reg. req.)

> Mental health pharmacogenomics company Assurex Health raked in $30 million to support development of its GeneSight neuropsychiatric products. Story

> Exact Sciences' ($EXAS) shares bounced back on Monday after the Centers for Medicare and Medicaid Services said that it made an error in the 2015 clinical lab fee schedule for the company's Cologuard test. More (reg. req.)

> VolitionRx is launching a clinical study at the University of Bonn in Germany to evaluate its lung cancer diagnostic platform. More

> CardioDx closed a $35 million financing round to support development of its genomic tests for coronary artery disease. More

And Finally… Proove Biosciences inked an exclusive licensing agreement with the University of North Carolina at Chapel Hill's School of Dentistry to incorporate its research on the genetics of pain perception into its diagnostic tests. More (reg. req.)

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.